Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers

November 2011
American Journal of Health-System Pharmacy;11/15/2011, Vol. 68 Issue 22, p2148
Academic Journal
Purpose. The pharmacokinetics, bioavailability, and tolerability of dalfampridine extended-release tablets in healthy adults under fed and fasted conditions were evaluated. Methods. The study participants (n = 30) were randomly assigned to receive one 10-mg dalfampridine tablet in a fasted condition (no food for 10-12 hours) or a fed condition (after a high-fat meal); after a seven-day washout period, participants received the same dalfampridine dosage under the converse condition. The endpoints were the maximum plasma drug concentration (Cmax) and areas under the plasma-concentration curve (AUC) for 24- hour exposure (AUC0-24) and total exposure (AUC0-∞). A 90% two-sided confidence interval (CI) within predefined limits for the fed:fasted ratio of the geometric mean values was used as the standard for determining the absence of a significant food effect. Results. Among the participants who received both treatments (n = 28), food intake was associated with a 23% increase in the log-transformed geometric mean Cmax of dalfampridine (p ≤0.10) but no significant change in mean AUC values. Eight (26.7%) of the study participants reported a total of 13 adverse events (AEs), of which only dizziness and upper abdominal pain occurred in more than one participant; all AEs were of mild-to-moderate severity. Conclusion. When a single 10-mg dose of dalfampridine was given to healthy volunteers after a high-fat meal, a significant increase in Cmax was observed. However, overall differences in dalfampridine pharmacokinetics when the drug was administered to participants under fasting and fed conditions did not exceed predefined limits, indicating that the extended-release formulation may be taken without regard to meals.


Related Articles

  • Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects. Shoaf, Susan; Mallikaarjun, Suresh; Bricmont, Patricia // European Journal of Clinical Pharmacology;Feb2012, Vol. 68 Issue 2, p207 

    Purpose: Tolvaptan is a selective vasopressin V2 receptor antagonist that can be given orally once daily for treatment of clinically significant hypervolemic and euvolemic hyponatremia (US and Europe) or extracellular volume expansion despite taking other diuretics (Japan). In vitro studies...

  • Melatonin: Can It Stop the Ringing? Hurtuk, Agnes; Dome, Claudia; Holloman, Christopher H.; Wolfe, Kelly; Welling, Bradley; Dodson, Edward E.; Jacob, Abraham // Annals of Otology, Rhinology & Laryngology;Jul2011, Vol. 120 Issue 7, p433 

    Objectives: We sought to report the efficacy of oral melatonin as treatment for chronic tinnitus and to determine whether particular subsets of tinnitus patients have greater benefit from melatonin therapy than others. Methods: This was a prospective, randomized, double-blind, crossover clinical...

  • Bioavalaibility and pharmacokinetic comparison of two formulations of metformin 850 mg tablets in healthy Colombian volunteers. HOLGUÍN, GLORIA; CUESTA, FANNY; ARCHBOLD, ROSENDO; RESTREPO, MARGARITA; PARRA, SERGIO; PEÑA, LINA; MONTOYA, BLANCA; RÍOS, JUAN CARLOS; TORO, VICTORIA EUGENIA; RUIZ, ADRIANA // Colombia Medica;ene-mar2011, Vol. 42 Issue 1, p81 

    Purpose: The aim of this study was to compare the bioavailability of two formulations of metformin 850 mg tablets: Glucophage® from Merck Santè laboratories (reference product) and Metformin from Winthrop Pharmaceuticals de Colombia SA (test product) in healthy Colombian volunteers....

  • Baseline Concussion Symptom Scores Vary by Method of Collection. Cripps, Andrea E.; Boham, Mikaela D. // International Journal of Athletic Therapy & Training;Jan2015, Vol. 20 Issue 1, p46 

    Context: The vast majority of athletic trainers administer preseason computerized inventories to document the presence of baseline symptoms; however, immediately following a concussion, athletic trainers frequently assess an athlete verbally or using a paper-based concussion symptom scale. The...

  • S-ketamine concentrations are greatly increased by grapefruit juice. Peltoniemi, Marko; Saari, Teijo; Hagelberg, Nora; Laine, Kari; Neuvonen, Pertti; Olkkola, Klaus // European Journal of Clinical Pharmacology;Jun2012, Vol. 68 Issue 6, p979 

    Purpose: We examined the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of oral S-ketamine. Methods: A randomized crossover open-label study design with two phases at an interval of 4 weeks was conducted in 12 healthy volunteers. Grapefruit juice or water was ingested...

  • Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers. Tan, Qin-You; Li, Huan-De; Zhu, Rong-Hua; Zhang, Qi-Zhi; Zhang, Jun; Peng, Wen-Xing // American Journal of Cardiovascular Drugs;Feb2013, Vol. 13 Issue 1, p17 

    Background and Objectives: Ranolazine was approved by the US Food and Drug Administration in January 2006 for the treatment of chronic angina pectoris, and is the first approved agent from a new class of anti-anginal drugs in almost 25 years. The primary objective of this study was to determine...

  • A Comparative Single Dose Bioequivalence Study of Extended Release Antihypertensive Drug Formulation among Healthy Human Volunteers. Deshpande, Supriya; Vijayrao Paithankar, Vivek // European Journal of General Medicine;2013, Vol. 10 Issue 2, p83 

    The objective of this study was to compare the in vivo characteristics of diltiazem extended release formulations for once daily, which were expected to be bioequivalent. Either two capsules of a test formulation or a 1 of the reference formulation, both containing 360 mg diltiazem were...

  • The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects. Xu, H. R.; Chen, W. L.; Chu, N. N.; Li, X. N.; Zhu, J. R. // Journal of Biomedicine & Biotechnology;2012, Vol. 2012, p1 

    The aim of this study was to evaluate the difference in pharmacokinetics and pharmacodynamics between extended-release (ER) fluvastatin tablet and its immediate-release (IR) capsule in Chinese healthy subjects. This was an open-label, single/multiple-dose, two-period, two-treatment, crossover,...

  • The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. Stringer, Frances; Scott, Graham; Valbuena, Marian; Kinley, Judith; Nishihara, Mitsuhiro; Urquhart, Richard // European Journal of Clinical Pharmacology;Mar2013, Vol. 69 Issue 3, p423 

    Purpose: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARγ, PPARα, and PPARδ. The compound undergoes phase II biotransformation by conjugation catalyzed by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics